Longeveron (LGVN)
Develops donor-derived cell therapy for pediatric cardiac and aging-related diseases.
Something off on this page? Send us feedback.
Develops laromestrocel, an investigational donor-derived cell therapy for pediatric cardiac and aging-related diseases, including HLHS and Alzheimer's disease. The clinical-stage business has no approved therapy sales, with all programs concentrated in the same candidate.
Develops laromestrocel (Lomecel-B), an investigational donor-derived mesenchymal stem-cell therapy, for hypoplastic left heart syndrome, mild Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. Its reported revenue comes from a Bahamas clinical-trial registry and third-party contract manufacturing rather than therapy sales.
Operates from Miami while running clinical activity across U.S. pediatric institutions. The lead HLHS program is being studied as an adjunct to staged surgery, while Alzheimer's and pediatric DCM development still depend on funding, partners, and trial execution. Every program depends on the same candidate, whose core cell-production technology is exclusively licensed from the University of Miami.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 11, 2026 | Maxim Group | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.1M · Total debt $581.0K · Total assets $15.5M · Shareholders' equity $10.4M
- Revenue
- $287.0K
- Operating income
- −$6.2M
- Net income
- −$6.1M
No dividends on record.
| Institutions | 14.94% | 476.3K shares | |
|---|---|---|---|
| 39 holders · as of Jun 30, 2026 | |||
| Insiders | 7.29% | 232.3K shares | |
| 12 holders · as of Aug 25, 2026 | |||
| Other | 77.77% | 2.48M shares | |
| remainder | |||
3.19M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Millennium Management LLCInstitution | 4.25% | 1.35M A | as of Jun 30, 2026 |
Logos Global Management LPInstitution | 4.04% | 1.29M A | as of Jun 30, 2026 |
Stephen H. WillardInsiderofficer: Chief Executive Officer | 2.42% | 77,168 A | filed Jul 6, 2026 |
Devin BlassInsiderofficer: CTO & SVP of CMC | 2.23% | 71,174 A | filed Aug 21, 2026 |
Vanguard Capital Management LLCInstitution | 1.82% | 581,305 A | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Mesoblast (ADR)
Direct HLHS rival with a broad cardiac cell-therapy platform.
- Eli Lilly
Approved Kisunla shapes the early Alzheimer's treatment pathway.
- BioCardia
Cardiac cell-therapy rival in clinical development for heart failure.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Longeveron | $2.76 | +12.65% | $7.5M | — | — | 6.3 | −9.2% |
| Mesoblast (ADR) | $15.98 | +3.22% | $2.01B | — | — | 16.6 | +391.8% |
| Eli Lilly | $1,171.24 | +0.55% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| BioCardia | $1.08 | +0.00% | $16.1M | — | — | — | — |
| Median | 39.1 | 28.6 | 15.2 | +219.7% |